Collaboration to collect Autologous transplant outcomes
in Lymphoma and Myeloma (CALM)

CALM

Non-Interventional Prospective Study
Inclusion period: 01/01/2008 – 31/12/2011

CENTRE REGISTRATION

Study

As a post-approval commitment to the European Medicines Agency (EMA), Genzyme in collaboration with the EBMT will compare outcomes of Lymphoma and Myeloma transplants in patients who receive plerixafor for mobilisation with patients who receive standard methods for mobilisation.

Centre eligibility criteria:

Do you treat adult patients (18 years or over) for Myeloma and/or Lymphoma? ☐ Yes
Did/do you perform autologous PBSCT between 01/01/2008 – 31/12/2011? ☐ Yes
Do you routinely use cells with one of the following mobilization regimens? ☐ Yes

Please mark the applicable

☐ **plerixafor + G-CSF**
☐ **plerixafor + G-CSF** + chemotherapy
☐ G-CSF alone
☐ G-CSF + chemotherapy

You must answer Yes to all questions in order to participate in this study.

Centre

EBMT Centre Identification Code (CIC) .....

Centre Address .....

.....

Contact person .....

Email address .....

Does your centre want to participate in this non-interventional prospective study?

☐ No reason: ……

☐ Yes

How many patients **per year** do you expect to include in this study ? I_I_I

Proposed Start Date : .... - .... - ....
dd mm yyyy

IDENTIFICATION & SIGNATURE

When participating:
I agree to include all consecutive eligible patients for the period 2008-2011 in this study and declare that the inclusion of any patient in this study will not affect the management of this patient.

..... Signature

..... Name

Please send the completed form to the EBMT data office in Leiden asap by using
Fax: **+49 180 500 290 623** (fax to e-mail system) or E-mail: **calmebmt@LUMC.NL**

Please send form to: Data Office Leiden
LUMC Postzone S-5-P
P.O. Box 9600
NL-2300 RC Leiden
The Netherlands
or fax +49-180-500-290-623 *or* +49-711-4900-872